These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 486305)

  • 21. Regional measurements of [14C]misonidazole distribution and blood flow in subcutaneous RT-9 experimental tumors.
    Blasberg R; Horowitz M; Strong J; Molnar P; Patlak C; Owens E; Fenstermacher J
    Cancer Res; 1985 Apr; 45(4):1692-701. PubMed ID: 3978636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative distribution of misonidazole and its amine metabolite in female Swiss Webster mice.
    Born JL; Hadley WM
    Int J Radiat Oncol Biol Phys; 1985 Jun; 11(6):1157-61. PubMed ID: 3997598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distribution and tumour cytotoxicity of the radiosensitizer misonidazole (Ro-07-0582) in C57 mice.
    Pedersen JE; Smith MR; Bugden RD; Peckham MJ
    Br J Cancer; 1979 Apr; 39(4):429-33. PubMed ID: 444398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the fate of misonidazole (RO 07-0582) and its metabolite desmethylmisonidazole (RO 05-9963), two hypoxic cell radiosensitizers: penetration properties in tumor bearing rats.
    Akel G; Canal P; Mockey E; Vandevoorde E; Laurent F; Soula G
    J Pharmacol; 1983; 14(1):67-77. PubMed ID: 6834852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phenytoin-induced changes in the pharmacokinetics of misonidazole in radiotherapy patients.
    Moore JL; Paterson IC; Newman H; Venables S
    Br J Cancer; 1981 Oct; 44(4):592-6. PubMed ID: 7295516
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs.
    White RA; Workman P
    Br J Cancer; 1980 Feb; 41(2):268-76. PubMed ID: 7370166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding of misonidazole to hypoxic cells in monolayer and spheroid culture: evidence that a side-chain label is bound as efficiently as a ring label.
    Raleigh JA; Franko AJ; Koch CJ; Born JL
    Br J Cancer; 1985 Feb; 51(2):229-35. PubMed ID: 3966980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absorption and distribution of vaginally administered misonidazole.
    Ash D; Bugden R; Calvert R
    Cancer Chemother Pharmacol; 1982; 9(2):118-9. PubMed ID: 7172406
    [No Abstract]   [Full Text] [Related]  

  • 29. The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole.
    White RA; Workman P; Brown JM
    Radiat Res; 1980 Dec; 84(3):542-61. PubMed ID: 6450431
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of phenytoin, phenobarbital, and ascorbic acid on misonidazole elimination.
    Williams K; Begg E; Wade D; O'Shea K
    Clin Pharmacol Ther; 1983 Mar; 33(3):314-21. PubMed ID: 6825387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A drug for improved radiosensitization in radiotherapy.
    Dische S; Fowler JF; Saunders MI; Stratford MR; Anderson P; Minchinton AI; Lee ME
    Br J Cancer; 1980 Jul; 42(1):153-5. PubMed ID: 7426325
    [No Abstract]   [Full Text] [Related]  

  • 32. The topical use of misonidazole in bladder cancer.
    Awwad HK; Abd El Moneim H; Abd El Baki H; Omar S; El Merzabani M; Farag HI
    Prog Clin Biol Res; 1983; 132D():305-16. PubMed ID: 6634802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Intraoperative radiotherapy in combination with misonidazole; with special reference to the drug concentrations in tumors and normal tissues and to the initial effect of the treatment].
    Takahashi M; Ono K; Hamanaka D; Dodo Y; Hiraoka M; Nishidai T; Abe M
    Nihon Igaku Hoshasen Gakkai Zasshi; 1983 Mar; 43(3):466-77. PubMed ID: 6310486
    [No Abstract]   [Full Text] [Related]  

  • 34. Anal submucosal injection: a new route for drug administration in pelvic malignancies. Part I. Experimental study of misonidazole distribution in serum and tissues, with special reference to urinary bladder. Preliminary report.
    Shafik A; el-Merzabani MM; el-Aaser AA; el-Desouky GH
    Invest Radiol; 1986 Mar; 21(3):278-81. PubMed ID: 3957602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of the hypoxic radiosensitizers misonidazole and demethylmisonidazole after intraperitoneal administration in humans.
    Gianni L; Jenkins JF; Greene RF; Lichter AS; Myers CE; Collins JM
    Cancer Res; 1983 Feb; 43(2):913-6. PubMed ID: 6848201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours.
    Brown JM; Yu NY; Workman P
    Br J Cancer; 1979 Mar; 39(3):310-20. PubMed ID: 465300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In situ drug delivery.
    Levin VA; Wright DC; Landahl HD; Patlak CS; Csejtey J
    Br J Cancer Suppl; 1980 Apr; 4():74-8. PubMed ID: 6932949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biliary and faecal excretion of misonidazole in man.
    Ash DV; Smith MR
    Br J Radiol; 1979 Oct; 52(622):846-8. PubMed ID: 509037
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of local hyperthermia on the pharmacokinetics of misonidazole in the anaesthetized mouse.
    Honess DJ; Workman P; Morgan JE; Bleehen NM
    Br J Cancer; 1980 Apr; 41(4):529-40. PubMed ID: 7387851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Misonidazole in the preoperative and radical radiotherapy of bladder cancer.
    Awwad HK; El Merzabani MM; El Badawy S; Ezzat S; Akoush H; Abd El Moneim H; Saiid A; Soliman O; Khafagy M; Burgers MV
    Cancer Clin Trials; 1980; 3(3):275-80. PubMed ID: 7438324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.